Publications by authors named "C Lluis-Ganella"
Background: The use of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is based on the results of robust clinical trials.
Objectives: To assess the effectiveness and safety of BIC/FTC/TAF in treatment-naïve (TN) and treatment-experienced (TE) people with HIV using available real-world cohort studies.
Methods: Systematic review and meta-analysis of publications and communications identified via Boolean search in Medline, PubMed and Embase, and conference abstracts reporting retrospective real-world use of BIC/FTC/TAF, published until 31 January 2024.
We examined the clinical utility of two multi-locus genetic risk scores (GRSs) previously validated in Europeans among persons of African (AFR; n = 2,089), Latino (LAT; n = 4,349) and East-Asian (EA; n = 4,804) ancestry. We used data from the GERA cohort (30-79 years old, 68 to 73% female). We utilized two GRSs with 12 and 51 SNPs, respectively, and the Framingham Risk Score (FRS) to estimate 10-year CHD risk.
View Article and Find Full Text PDFObesity is associated with increased risk of several diseases and has become epidemic. Obesity is highly heritable but the genetic variants identified by genome-wide association studies explain only limited variability. Epigenetics could contribute to explain the missing variability.
View Article and Find Full Text PDFArticle Synopsis
- Genetic screening in patients with high LDL-C levels has revealed a significant prevalence of familial hypercholesterolemia (FH) in individuals with acute coronary syndrome (ACS), reaching about 9%.
- Clinical criteria used to diagnose FH, such as those from the Dutch Lipid Clinic (DLC) and Simon Broome (SB), often miss a notable number of genetically confirmed cases.
- The study advocates for genetic testing in younger patients with ACS and high LDL-C to ensure quick identification of FH patients and their at-risk relatives.